Effects of Cyclosporine 0.05% Ophthalmic Emulsion to Improve Reduction of Tear Production after Cataract Surgery

Ri Yoo Ae; Bin Hwang Hyung; Kyung Kim Hyun; Kun Chung Sung

doi:10.3341/jkos.2013.54.7.1013

Journal List > J Korean Ophthalmol Soc > v.54(7) > 1009413

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ae, Hyung, Hyun, and Sung: Effects of Cyclosporine 0.05% Ophthalmic Emulsion to Improve Reduction of Tear Production after Cataract Surgery

Original Article

J Korean Ophthalmol Soc 2013;54(7):1013-1018.

Published online: 7 September 2013

DOI: https://doi.org/10.3341/jkos.2013.54.7.1013

Effects of Cyclosporine 0.05% Ophthalmic Emulsion to Improve Reduction of Tear Production after Cataract Surgery

Ri Yoo Ae, MD¹, Bin Hwang Hyung, MD¹, Kyung Kim Hyun, MD, PhD², Kun Chung Sung, MD, PhD¹

¹Department of Ophthalmology and Visual Science, St. Mary’s Hospital¹,

²St. Vincent’s Hospital², The Catholic University of Korea College of Medicine, Seoul, Korea

Address reprint requests to Sung Kun Chung, MD, PhD Department of Ophthalmology, The Catholic University of Korea Yeouido St. Mary’s Hospital, #10 63-ro, Yeongdeungpo-gu, Seoul 150-713, Korea Tel: 82-2-3779-1243, Fax: 82-2-761-6869 E-mail: eyedoc@catholic.ac.kr

Received 7 July 201211 January 2013 Accepted 3 May 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To evaluate the efficacy of cyclosporine 0.05% in reduced tear production sign and dry eye symptoms after cata-ract surgery.

Methods

This hospital-based prospective randomized trial included 43 patients of 83 eyes who underwent phacoemulsification. Tear break-up time, Schirmer’s test, corneal and conjunctival stain, and ocular surface disease index were performed for all pa-tients at preoperative 1 day, and 1 day, 1 week, 1 month, and 2 months postoperatively. Group 1 received carboxymethylcellulose 0.5%, group 2 received twice-daily cyclosporine 0.05%, and group 3 did not receive any additional eye drops.

Results

There was no statistically significant difference between the 3 groups in outcome measures. Two months after cataract surgery, the cyclosporine group showed improved tear break-up time, Schirmer’s test I, and corneal and con-junctival staining.

Conclusions

Cyclosporine 0.05% therapy reduced dry eye signs and symptoms after cataract surgery.

Go to :

Keywords: Cataract surgery, Cyclosporine, Dry eye, Phacoemulsification

References

1. Begley CG, Caffery B, Nichols K, et al. Results of a dry eye ques-tionnarire from optometric practices. Adv Exp Med Biol. 2002; 506(Pt B):1009–16.

2. Holly FJ. Surface chemical evaluation of artificial tears and their ingredients, II. Interaction with a superficial lipid layer. Eye Contact Lens. 1978; 4:52–65.

3. Li XM, Hu L, Hu J, Wang W. Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1):16–20.

4. Oh T, Jung Y, Chang D, et al. Changes in the tear film and ocular surface after cataract surgery. Jpn J Ophthalmol. 2012; 56:113–8.

5. Hoffman RS, Fine IH, Packer M. New phacoemulsification technology. Curr Opin Opthalmol. 2005; 16:38–43.

6. Khanal S, Tomlinson A, Esakowitz L, et al. Changes in corneal sen-sitivity and tear physiology after phacoemulsification. Ophthalmic Physiol Opt. 2008; 28:127–34.

7. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine oph-thalmic emulsion in moderate to severe dry eye disease. the CsA Phase 3 Study Group. Ophthalmology. 2000; 107:631–9.

8. Donnenfeld ED, Solomon R, Roberts CW, et al. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. J Cataract Refract Surg. 2010; 36:1095–100.

9. Schhiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000; 118:615–21.

10. Preschel N, Hardten DR. Management of coincident corneal dis-ease and cataract. Curr Opin Ophthalmol. 1999; 10:59–65.

11. Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J. 2000; 26:159–65.

12. Peppas NA, Buri PA. Surface, interfacial and molecular aspects of polymer bioadhesion of soft tissues. J Controll Release. 1985; 2:257–75.

13. Hunt G, Kearney P, Kellaway IW. Mucoadhesive polymers in drug delivery systems fundamentals and techniques. Weinheim:: Germany VCH;1987. p. 180–99.

14. Lee JH, Ahn HS, Kim EK, Kim TI. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011; 30:175–9.

15. Grene RB, Lankston P, Mordaunt J, et al. Unpreserved carbox-ymethylcellulose artificial tears evaluated in patients with kerato-conjunctivitis sicca. Cornea. 1992; 11:294–301.

16. Byun YS, Rho CR, Cho K, et al. Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-la-bel, surveillance study. Korean J Ophthalmol. 2011; 25:369–74.

17. Byun YJ, Kim TI, Seo KY. The short-term effect of topical cyclo-sporine 0.05% in various ocular surface disorder. J Korean Ophthalmol Soc. 2008; 49:401–8.

18. Preschel N, Hardten DR. Management of coincident corneal dis-ease and cataract. Curr Opin Ophthalmol. 1999; 10:59–65.

19. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and manage-ment of dry eye: a twenty-ive-year review. Cornea. 2000; 19:644–9.

20. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17:584–9.

21. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal func-tional unit in the pathophysiology of dry eye. Exp Eye Res. 2004; 78:409–16.

22. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112:1790–4.

Go to :

Figure 1.

Tear Break up time (TBUT) at pre-op and post-op 1 day, 1 week, 1 month, and 2 months. The increase in TBUT was statistically significant between1 month and 2 months (Group 1 = Carboxymethylcellulose 0.5%, Group 2 = Cyclosporine 0.05%, Group 3 = No additional eye drops).

undefined

Figure 2.

Schirmer test I at pre-op and post-op 1 day, 1 week, 1 month, and 2 months. Schirmer test I of group 2 increased statistically significant between post-op 1 month and 2 months (Group 1 = Carboxymethylcellulose 0.5%, Group 2 = Cyclosporine 0.05%, Group 3 = No additional eye drops).

undefined

Figure 3.

Corneal and conjunctival staining at pre-op and post-op 1 month, 2 months. Group 2 had lowered corneal and conjunctival staining grades 2 months after cataract surgery (Group 1 = Carboxymethylcellulose 0.5%, Group 2 = Cyclos- porine 0.05%, Group 3 = No additional eye drops).

undefined

Figure 4.

Mean ocular surface disease index (OSDI) score at pre-op and after surgery. The OSDI score decreased more in group1 and 2 than group 3 from 1 week after surgery to 2 month (Group 1 = Carboxymethylcellulose 0.5%, Group 2 = Cyclosporine 0.05%, Group 3 = No additional eye drops).

undefined

Table 1.

Baseline data by treatment

Parameter	Group 1^*	Treatment Group 2^†	Group 3^‡	p-value
Tear film break up time	7.46 ± 1.5	7.75 ± 1.4	7.43 ± 1.7	0.704
Schirmer test I	10.58 ± 2.5	10.59 ± 2.5	10.57 ± 2.4	1.000
Corneal & conjunctival stain	1.77 ± 0.15	1.83 ± 0.18	1.64 ± 0.17	0.760
Ocular surface disease index	23.33 ± 4.3	23.38 ± 4.1	23.38 ± 4.4	0.085

Values are presented as mean ± SD.

^* Carboxymethylcellulose 0.5%

^† Cyclosporine 0.05%

^‡ No additional eye drops.

Table 2.

Tear film break up time

Parameter		Treatment		p-value
Parameter	Group 1^*	Group 2^†	Group 3^‡	p-value
POD 1 day	5.08 ± 2.01	5.19 ± 1.97	5.18 ± 2.10	0.881
POD 1 week	5.10 ± 2.03	5.22 ± 1.85	5.23 ± 2.13	0.781
POD 1 month	5.42 ± 2.01	6.04 ± 2.03	5.39 ± 2.21	0.006
POD 2 months	5.79 ± 1.98	7.29 ± 2.01	5.96 ± 1.98	0.003

Values are presented as mean ± SD.

^* Carboxymethylcellulose 0.5%

^† Cyclosporine 0.05%

^‡ No additional eye drops.

Table 3.

Schirmer test I

Parameter		Treatment		p-value
Parameter	Group 1^*	Group 2^†	Group 3^‡	p-value
POD 1 day	8.77 ± 2.4	9.46 ± 2.2	8.29 ± 2.1	0.133
POD 1 week	8.56 ± 2.1	8.87 ± 2.3	8.33 ± 2.2	0.147
POD 1 month	8.52 ± 2.3	9.52 ± 2.3	8.32 ± 2.2	0.152
POD 2 months	8.30 ± 2.5	10.83 ± 2.2	8.07 ± 2.1	0.003

Values are presented as mean ± SD.

^* Carboxymethylcellulose 0.5%

^† Cyclosporine 0.05%

^‡ No additional eye drops.

Table 4.

Corneal & Conjunctival staining

Parameter		Treatment		p-value
Parameter	Group 1^*	Group 2^†	Group 3^‡	p-value
POD 1 day	1.08 ± 0.22	1.17 ± 0.21	1.17 ± 0.17	0.142
POD 1 week	1.12 ± 0.14	1.24 ± 0.18	1.17 ± 0.15	0.130
POD 1 month	1.32 ± 0.17	1.25 ± 0.15	1.22 ± 0.19	0.152
POD 2 months	1.42 ± 0.15	0.88 ± 0.14	1.33 ± 0.17	0.004

Values are presented as mean ± SD.

^* Carboxymethylcellulose 0.5%

^† Cyclosporine 0.05%

^‡ No additional eye drops.

Table 5.

OSDI score

Parameter		Treatment		p-value
Parameter	Group 1^*	Group 2^†	Group 3^‡	p-value
POD 1 week	26.33 ± 4.3	25.33 ± 4.2	26.38 ± 4.2	0.090
POD 1 month	25.44 ± 4.7	25.38 ± 4.4	25.38 ± 3.7	0.072
POD 2 months	23.33 ± 4.6	23.33 ± 4.2	23.38 ± 4.2	0.061

Values are presented as mean ± SD.

^* Carboxymethylcellulose 0.5%

^† Cyclosporine 0.05%

^‡ No additional eye drops.

TOOLS

Similar articles